Track Evolus, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Evolus, Inc. EOLS Open Evolus, Inc. in new tab

6.57 USD
EPS
-0.66
P/B
-17.94
ROE
-18729.61
Beta
1.29
Target Price
14.67 USD
Evolus, Inc. logo

Evolus, Inc.

🧾 Earnings Recap – Q3 2025

Evolus delivered a strong third quarter with a 13% revenue increase driven by robust demand for Jeuveau and promising early results from the Evolysse launch, positioning the company for sustainable profitability by 2026.

  • Jeuveau unit sales grew consistently, achieving a 14% share of the U.S. market.
  • Evolysse generated $5.7 million in revenue during its third quarter, marking the strongest debut for a HA filler in over a decade.
  • The Evolus Rewards program saw total redemptions rise 34%, reinforcing consumer loyalty with 70% of members being repeat customers.
  • The company remains focused on efficiency as it prepares to bundle products, encouraging cross-selling while expanding its customer base to over 17,000 accounts.
📅
Loading chart...
Key Metrics
Earnings dateAug. 4, 2026
EPS-0.66
Book Value-0.36
Price to Book-17.94
Debt/Equity2205.01
% Insiders14.683%
Growth
Revenue Growth0.14%
Estimates
Forward P/E28.00
Forward EPS0.23
Target Mean Price14.67

DCF Valuation

Tweak assumptions to recompute fair value for Evolus, Inc. (EOLS)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
Current Price
Upside
WACC
Terminal PV
Σ PV of FCFs
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Evolus, Inc. Logo Evolus, Inc. Analysis (EOLS)

United States Health Care Official Website Stock

Is Evolus, Inc. a good investment? Evolus, Inc. (EOLS) is currently trading at 6.57 USD. Market analysts have a consensus price target of 14.67 USD. This suggests a potential upside from current levels.

Earnings Schedule: Evolus, Inc. is expected to release its next earnings report on Aug. 4, 2026. The market consensus estimate for Forward EPS is 0.23.

Investor FAQ

Does Evolus, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Evolus, Inc.?

Evolus, Inc. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Aug. 4, 2026. The company currently has a trailing EPS of -0.66.

Company Profile

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Exchange Ticker
NMS (United States) EOLS
FRA (Germany) EVL.F
LSE (United Kingdom) 0K16.L

Dividends

Historical Split Corporate Actions

Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion